ReviewFrontiers in oncology2022
Reduced Cancer Screening Due to Lockdowns of the COVID-19 Pandemic: Reviewing Impacts and Ways to Counteract the Impacts.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Initial and persistent changes in cancer screening in a US Midwestern community health center network following the onset of COVID-19.Preventive medicine reports · 2025Article
- The impact of the pandemic on non-COVID-19 causes of death in the United States: a multiple cause of death analysis.European journal of epidemiology · 2025Article
- SARS-CoV-2 Infection and the Risk of New Chronic Conditions: Insights from a Longitudinal Population-Based Study.International journal of environmental research and public health · 2025Article
- Melanoma detection, treatment, survival, and mortality through year 2 of the pandemic.Archives of dermatological research · 2025Article
- Anogenital HPV-Related Cancers in Women: Investigating Trends and Sociodemographic Risk Factors.Cancers · 2024Article
- A pharmacist-led community-based survey study: Determining the impact of the Covid-19 pandemic on actionable factors associated with worse cancer outcomes and cancer health disparities.Exploratory research in clinical and social pharmacy · 2023Article
- Disseminated tuberculosis and diagnosis delay during the COVID-19 era in a Western European country: a case series analysis.Frontiers in public health · 2023Article
- Impact of the COVID-19 pandemic on primary brain tumor incidence and management: Decisions that went right.Neuro-oncology advancesArticle
- Suboptimal Quality of Health Care and Associated Socioeconomic Factors Among Cancer Survivors During the COVID-19 Pandemic: A Cross-Sectional Study.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has created disruptions in health services in general and cancer screening and diagnostic services in particular, leading to diminished cancer screening participation rates. This paper aims to seek insights into impacts that the pandemic has had on cancer screening, impacts that reduced cancer screening may have in the long run, and how to address such impacts. The paper demonstrates that reduced cancer screening in the pandemic is likely to result in enhanced demands for cancer screening in the new normal, enhanced demands for resources to address such demands, and poor prognosis due to stage migration of cancer diseases. Some measures are recommended for counteracting these impacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.